Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.9405
-0.1295 (-12.10%)
At close: May 26, 2026, 4:00 PM EDT
0.9547
+0.0142 (1.51%)
After-hours: May 26, 2026, 5:27 PM EDT
RANI Revenue
Rani Therapeutics Holdings had revenue of $1.71M in the quarter ending March 31, 2026, with 893.02% growth. This brings the company's revenue in the last twelve months to $3.17M, up 164.08% year-over-year. In the year 2025, Rani Therapeutics Holdings had annual revenue of $1.63M with 58.85% growth.
Revenue (ttm)
$3.17M
Revenue Growth
+164.08%
P/S Ratio
30.41
Revenue / Employee
$44,634
Employees
71
Market Cap
93.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.63M | 605.00K | 58.85% |
| Dec 31, 2024 | 1.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 2.72M | 2.26M | 488.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRANI News
- 9 hours ago - Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 11 days ago - Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - GlobeNewsWire
- 11 days ago - Rani Therapeutics Holdings Quarterly report: Q1 2026 - Filings
- 11 days ago - Rani Therapeutics Holdings Earnings release: Q1 2026 - Filings
- 14 days ago - Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference - GlobeNewsWire
- 5 weeks ago - Rani Therapeutics Holdings Proxy statement: Proxy filing - Filings
- 5 weeks ago - Rani Therapeutics Holdings Proxy statement: Proxy filing - Filings
- 6 weeks ago - Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy - GlobeNewsWire